Dehydroepiandrosterone administration before IVF in poor responders

A prospective cohort study

Nikos Vlahos, Maria Papalouka, Olga Triantafyllidou, Athanasios Vlachos, Panagiotis Vakas, Gregory Grimbizis, George Creatsas, Konstantinos Zikopoulos

Research output: Contribution to journalArticle

Abstract

The use of dehydroepiandrosterone (DHEA) may improve ovarian stimulation outcomes in women of advanced reproductive age and could reduce embryo aneuploidy. In this prospective study, 48 women diagnosed with poor ovarian response received DHEA supplementation for at least 12 weeks. These women were compared with a group of poor responders (n = 113) who did not receive supplementation. During the study period, patients taking day 2 FSH and oestradiol were measured monthly before and after treatment. Stimulation characteristics, stimulation outcome and clinical outcome (clinical pregnancy and live birth rates) were reported. Evaluation of anti-Müllerian hormone (AMH) was carried out before initiation of treatment and immediately before the subsequent stimulation. Supplementation with DHEA for at least 12 weeks resulted in a modest, but statistically significant, increase in AMH levels and decrease in baseline FSH (P <0.001 and P = 0.007, respectively). Administration of DHEA had no effect on any of the stimulation parameters nor was there any difference in clinical pregnancy rates and live birth rates between the two groups. Supplementation with DHEA significantly affects women with poor prognosis undergoing ovarian stimulation for IVF. Patients should be counselled about the uncertain effectiveness, potential side-effects and cost of this treatment.

Original languageEnglish (US)
Pages (from-to)191-196
Number of pages6
JournalReproductive BioMedicine Online
Volume30
Issue number2
DOIs
StatePublished - Feb 1 2015
Externally publishedYes

Fingerprint

Dehydroepiandrosterone
Cohort Studies
Prospective Studies
Ovulation Induction
Pregnancy Rate
Hormones
Birth Rate
Aneuploidy
Health Care Costs
Estradiol
Embryonic Structures
Therapeutics

Keywords

  • AMH
  • DHEA
  • IVF
  • ovarian response
  • ovarian stimulation

ASJC Scopus subject areas

  • Reproductive Medicine
  • Developmental Biology
  • Medicine(all)

Cite this

Vlahos, N., Papalouka, M., Triantafyllidou, O., Vlachos, A., Vakas, P., Grimbizis, G., ... Zikopoulos, K. (2015). Dehydroepiandrosterone administration before IVF in poor responders: A prospective cohort study. Reproductive BioMedicine Online, 30(2), 191-196. https://doi.org/10.1016/j.rbmo.2014.10.005

Dehydroepiandrosterone administration before IVF in poor responders : A prospective cohort study. / Vlahos, Nikos; Papalouka, Maria; Triantafyllidou, Olga; Vlachos, Athanasios; Vakas, Panagiotis; Grimbizis, Gregory; Creatsas, George; Zikopoulos, Konstantinos.

In: Reproductive BioMedicine Online, Vol. 30, No. 2, 01.02.2015, p. 191-196.

Research output: Contribution to journalArticle

Vlahos, N, Papalouka, M, Triantafyllidou, O, Vlachos, A, Vakas, P, Grimbizis, G, Creatsas, G & Zikopoulos, K 2015, 'Dehydroepiandrosterone administration before IVF in poor responders: A prospective cohort study', Reproductive BioMedicine Online, vol. 30, no. 2, pp. 191-196. https://doi.org/10.1016/j.rbmo.2014.10.005
Vlahos, Nikos ; Papalouka, Maria ; Triantafyllidou, Olga ; Vlachos, Athanasios ; Vakas, Panagiotis ; Grimbizis, Gregory ; Creatsas, George ; Zikopoulos, Konstantinos. / Dehydroepiandrosterone administration before IVF in poor responders : A prospective cohort study. In: Reproductive BioMedicine Online. 2015 ; Vol. 30, No. 2. pp. 191-196.
@article{fc60db58c9b84521be598951e231e4e0,
title = "Dehydroepiandrosterone administration before IVF in poor responders: A prospective cohort study",
abstract = "The use of dehydroepiandrosterone (DHEA) may improve ovarian stimulation outcomes in women of advanced reproductive age and could reduce embryo aneuploidy. In this prospective study, 48 women diagnosed with poor ovarian response received DHEA supplementation for at least 12 weeks. These women were compared with a group of poor responders (n = 113) who did not receive supplementation. During the study period, patients taking day 2 FSH and oestradiol were measured monthly before and after treatment. Stimulation characteristics, stimulation outcome and clinical outcome (clinical pregnancy and live birth rates) were reported. Evaluation of anti-M{\"u}llerian hormone (AMH) was carried out before initiation of treatment and immediately before the subsequent stimulation. Supplementation with DHEA for at least 12 weeks resulted in a modest, but statistically significant, increase in AMH levels and decrease in baseline FSH (P <0.001 and P = 0.007, respectively). Administration of DHEA had no effect on any of the stimulation parameters nor was there any difference in clinical pregnancy rates and live birth rates between the two groups. Supplementation with DHEA significantly affects women with poor prognosis undergoing ovarian stimulation for IVF. Patients should be counselled about the uncertain effectiveness, potential side-effects and cost of this treatment.",
keywords = "AMH, DHEA, IVF, ovarian response, ovarian stimulation",
author = "Nikos Vlahos and Maria Papalouka and Olga Triantafyllidou and Athanasios Vlachos and Panagiotis Vakas and Gregory Grimbizis and George Creatsas and Konstantinos Zikopoulos",
year = "2015",
month = "2",
day = "1",
doi = "10.1016/j.rbmo.2014.10.005",
language = "English (US)",
volume = "30",
pages = "191--196",
journal = "Reproductive BioMedicine Online",
issn = "1472-6483",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Dehydroepiandrosterone administration before IVF in poor responders

T2 - A prospective cohort study

AU - Vlahos, Nikos

AU - Papalouka, Maria

AU - Triantafyllidou, Olga

AU - Vlachos, Athanasios

AU - Vakas, Panagiotis

AU - Grimbizis, Gregory

AU - Creatsas, George

AU - Zikopoulos, Konstantinos

PY - 2015/2/1

Y1 - 2015/2/1

N2 - The use of dehydroepiandrosterone (DHEA) may improve ovarian stimulation outcomes in women of advanced reproductive age and could reduce embryo aneuploidy. In this prospective study, 48 women diagnosed with poor ovarian response received DHEA supplementation for at least 12 weeks. These women were compared with a group of poor responders (n = 113) who did not receive supplementation. During the study period, patients taking day 2 FSH and oestradiol were measured monthly before and after treatment. Stimulation characteristics, stimulation outcome and clinical outcome (clinical pregnancy and live birth rates) were reported. Evaluation of anti-Müllerian hormone (AMH) was carried out before initiation of treatment and immediately before the subsequent stimulation. Supplementation with DHEA for at least 12 weeks resulted in a modest, but statistically significant, increase in AMH levels and decrease in baseline FSH (P <0.001 and P = 0.007, respectively). Administration of DHEA had no effect on any of the stimulation parameters nor was there any difference in clinical pregnancy rates and live birth rates between the two groups. Supplementation with DHEA significantly affects women with poor prognosis undergoing ovarian stimulation for IVF. Patients should be counselled about the uncertain effectiveness, potential side-effects and cost of this treatment.

AB - The use of dehydroepiandrosterone (DHEA) may improve ovarian stimulation outcomes in women of advanced reproductive age and could reduce embryo aneuploidy. In this prospective study, 48 women diagnosed with poor ovarian response received DHEA supplementation for at least 12 weeks. These women were compared with a group of poor responders (n = 113) who did not receive supplementation. During the study period, patients taking day 2 FSH and oestradiol were measured monthly before and after treatment. Stimulation characteristics, stimulation outcome and clinical outcome (clinical pregnancy and live birth rates) were reported. Evaluation of anti-Müllerian hormone (AMH) was carried out before initiation of treatment and immediately before the subsequent stimulation. Supplementation with DHEA for at least 12 weeks resulted in a modest, but statistically significant, increase in AMH levels and decrease in baseline FSH (P <0.001 and P = 0.007, respectively). Administration of DHEA had no effect on any of the stimulation parameters nor was there any difference in clinical pregnancy rates and live birth rates between the two groups. Supplementation with DHEA significantly affects women with poor prognosis undergoing ovarian stimulation for IVF. Patients should be counselled about the uncertain effectiveness, potential side-effects and cost of this treatment.

KW - AMH

KW - DHEA

KW - IVF

KW - ovarian response

KW - ovarian stimulation

UR - http://www.scopus.com/inward/record.url?scp=84922596431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922596431&partnerID=8YFLogxK

U2 - 10.1016/j.rbmo.2014.10.005

DO - 10.1016/j.rbmo.2014.10.005

M3 - Article

VL - 30

SP - 191

EP - 196

JO - Reproductive BioMedicine Online

JF - Reproductive BioMedicine Online

SN - 1472-6483

IS - 2

ER -